Document is current
Any future updates will be listed below
-
Authors
Jamy, Omer
El Kettani, Mobachir
Shah, Kashish
Shallis, Rory M.
Diebold, Kendall
Coltoff, Alexander
Goldberg, Aaron D.
Patel, Anand https://orcid.org/0000-0002-0296-8686
Bewersdorf, Jan P. https://orcid.org/0000-0003-3352-0902
Foucar, Charles
Abaza, Yasmin https://orcid.org/0000-0002-9156-7912
Palmisiano, Neil
DuVall, Adam S. https://orcid.org/0000-0002-9163-8792
Kota, Vamsi https://orcid.org/0000-0002-5290-9289
Patel, Shyam A. https://orcid.org/0000-0002-8208-1902
Zeidan, Amer M.
Atallah, Ehab
Litzow, Mark R. https://orcid.org/0000-0002-9816-6302
Badar, Talha https://orcid.org/0000-0003-1548-918X
- License Information
-
More Information
Article History
Received: 1 July 2025
Revised: 18 August 2025
Accepted: 9 September 2025
First Online: 7 October 2025
Competing interests
: OJ; Advisory board for Ascentage, Sobi, Maat, and TERN, AP; Research funding from Kronos Bio, Sumitomo, Servier, Incyte, Pfizer; Honoraria for advisory boards from Sobi, AbbVie. CF; Advisory board, Stemline, and Honoraria from Binaytara Foundation. CL; Advisory board for ADC Therapeutics, Autolus, Consulting: Rigel. SAP served on the Acute Leukemia Advisory Board for Syndax and the MDS Advisory Board for Bristol Myers Squibb.
: This study was conducted following approval from the Institutional Review Board (IRB #21-002315) and in accordance with the ethical principles outlined in the Declaration of Helsinki (1975, as revised in 2000). Informed consent was waived due to the retrospective nature of the study.
